{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-050987","form_type":"8-K","ticker":"ALGS","cik":"0001799448","company_name":"Aligos Therapeutics, Inc.","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.572622+00:00","generated_at":"2026-06-05T09:15:38.268509+00:00","sec_items":["5.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Aligos Therapeutics completes stock option exchange; 93% of eligible underwater options surrendered.","bullets":["Option exchange program closed; 3,880,332 shares surrendered (~93% of eligible) for 1,906,153 replacement options.","CEO Lawrence M. Blatt surrendered 854,250 options, received 421,100 replacement options; other NEOs and directors also participated.","Exchange ratios were 1.4-for-1 or 3.4-for-1 based on exercise price; all surrendered options were underwater.","Replacement options have a new one-year cliff vest from grant date (Feb 28, 2024), then follow original schedule."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-050987","json":"https://secwatch.observer/filing/0001193125-24-050987.json","markdown":"https://secwatch.observer/filing/0001193125-24-050987.md","text":"https://secwatch.observer/filing/0001193125-24-050987.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799448/000119312524050987/0001193125-24-050987-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799448/000119312524050987/d766112d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T09:15:38.268509+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}